TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05174793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dehydration and rehydration
Description: dehydration and rehydration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dehydration and rehydration
Description: dehydration and rehydration
Study: NCT03880630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
Study: NCT00129922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study: NCT03060655

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLGA-Mg material
Description: The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: titanium alloy
Description: Traditional fixation was titanium alloy. the clinical outcome was assessed.
Study: NCT05356754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vital Labs Digital Blood Pressure Monitor
Description: The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
Study: NCT04744857

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
Description: Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
Study: NCT00317889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone preparation technique: compaction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone preparation technique: broaching
Study: NCT04246983

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Opportunistic infection Ultrasound (OpUS) screening
Description: this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
Study: NCT01009879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg SQ qweek
Study: NCT01127880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ancef or Clindamycin
Description: 1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: .9% Normal Saline as a placebo
Study: NCT00840801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
Description: Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
Description: Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
Study: NCT00045708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticonvulsant
Description: Drugs that induce hepatic Metabolic enzymes
Study: NCT02617875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional EMS physician
Description: A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.

Intervention type: OTHER
Group type: OTHER
Intervention: tele-EMS physician
Description: The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
Study: NCT04665154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: single dose i.v. and s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: single dose i.v. and s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose i.v. and s.c.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose i.v. and s.c.
Study: NCT02273284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
Study: NCT02943941

Intervention type: OTHER
Group type: OTHER
Intervention: Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.
Description: Cardiac Monitor with LINQ™ HF Investigational RAMware download
Study: NCT03790995

Intervention type: PROCEDURE
Intervention: Robot assisted laparoscopic prostatectomy

Intervention type: PROCEDURE
Intervention: Robot assisted laparoscopic prostatectomy
Study: NCT02880592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affinity Allograft
Description: fresh hypothermically stored human amniotic membrane

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: offloading, debridement, infection management using appropriate dressings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: offloading, debridement, infection management using appropriate dressings
Study: NCT03917940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral
Description: Omega 3 fatty acids 1000 mg per day oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: glimepiride 2 mg or 3 mg per day oral
Study: NCT01321554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.
Study: NCT03519750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 25 mg
Description: 24-48 hour monitoring of plasma melatonin as well as adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg
Description: 24-48 hour monitoring of plasma melatonin as well as adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg
Description: 24-48 hour monitoring of plasma melatonin as well as adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg
Description: 24-48 hour monitoring of plasma melatonin as well as adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg
Description: 24-48 hour monitoring of plasma melatonin as well as adverse events.
Study: NCT02573480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wraparound care
Description: Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
Study: NCT01331057

Intervention type: OTHER
Intervention: NEEL test
Description: An assessment for children in French with items extracted from the NEEL test

Intervention type: OTHER
Intervention: NEEL test
Description: An assessment for children in French with items extracted from the NEEL test

Intervention type: OTHER
Intervention: NEEL test
Description: An assessment for children in French with items extracted from the NEEL test

Intervention type: OTHER
Intervention: ELAL test
Description: An assessment of mother tongue with the ELAL of AVICENNE

Intervention type: OTHER
Intervention: ELAL test
Description: An assessment of mother tongue with the ELAL of AVICENNE

Intervention type: OTHER
Intervention: ELAL test
Description: An assessment of mother tongue with the ELAL of AVICENNE

Intervention type: OTHER
Intervention: Interview
Description: For parents of children include in the study: A semi -structured interview

Intervention type: OTHER
Intervention: Interview
Description: For parents of children include in the study: A semi -structured interview

Intervention type: OTHER
Intervention: Interview
Description: For parents of children include in the study: A semi -structured interview
Study: NCT00432874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound hydration method
Description: Anterior vs lateral wound hydration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound hydration method
Description: Anterior vs lateral wound hydration
Study: NCT02034825

Intervention type: OTHER
Intervention: Decipher Questionnaire
Description: Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
Study: NCT04437420

Intervention type: DRUG
Intervention: injection of BEP 800
Description: injection of BEP 800

Intervention type: DRUG
Intervention: injection of BEP 800
Description: injection of BEP 800

Intervention type: OTHER
Intervention: Control
Description: no injection of BEP 800

Intervention type: OTHER
Intervention: Control
Description: no injection of BEP 800
Study: NCT03753451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treatment of periodontal disease
Description: Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treatment of periodontal disease
Description: Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.
Study: NCT02238925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Study: NCT04219852

Intervention type: OTHER
Intervention: data collection
Description: data collection
Study: NCT01957917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAC (Nutritional Assessment and Counseling)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAC (Nutritional Assessment and Counseling)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NAC (Nutritional Assessment and Counseling)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Assistance
Study: NCT02200263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein plus Zeaxanthin
Description: dose: two softgels once a day with a meal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two softgels once-daily with a meal
Study: NCT01953614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic adjustment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham adjustment
Study: NCT03727009

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study: NCT02584725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Comparison of 3 different doses of the drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Comparison of 3 different doses of the drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Comparison of 3 different doses of the drug
Study: NCT01475695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C GSK2251052
Description: 1500 mg iv dose GSK2251052
Study: NCT03536364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Order
Description: carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate Last
Description: protein and vegetables first, followed 10 minutes later by carbohydrate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegetables first
Description: vegetables first, followed 10 mins later by protein and carbohydrate.
Study: NCT02243644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of albendazole 15 mg/kg/day
Description: group A will receive 7 days of oral albendazole 15 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28 days of albendazole 15 mg/kg/day
Description: group B will receive 28 days of oral albendazole 15 mg/kg/day
Study: NCT01900262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Participants will be asked to compete 8 weeks of functional balance training at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
Study: NCT04128293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Capsule
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Capsule
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Capsule
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Capsule
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Study: NCT01325025

Intervention type: OTHER
Group type: OTHER
Intervention: High-field MRI (3 Teslas)
Description: * anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence

Intervention type: OTHER
Group type: OTHER
Intervention: High-field MRI (3 Teslas)
Description: * anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence
Study: NCT03287739

Intervention type: BEHAVIORAL
Intervention: Assessment of behavioral biometric impairments
Description: Assessment of behavioral biometric impairments
Study: NCT03175627

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek One
Description: Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Z250
Description: Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
Study: NCT04557839

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy balance exercise
Description: first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioception based balance training
Description: first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~* eyes open firm surfaces~* Eyes open soft surfaces~* Eyes closed firm surfaces~* Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~* These exercise will perform with turning the head side to side ad up and down~* Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training
Study: NCT03760601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive intervention
Description: A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
Study: NCT02540694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosonography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosonography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosonography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosonography
Study: NCT00992953

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: 10 weeks of therapy and/or psychiatric medication as available

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure with Stimulus Control
Description: 10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
Study: NCT02026856

Intervention type: DRUG
Intervention: sodium selenite pentahydrate

Intervention type: DRUG
Intervention: sodium selenite pentahydrate

Intervention type: OTHER
Intervention: placebo - continuous saline NaCl 50 ml

Intervention type: OTHER
Intervention: placebo - continuous saline NaCl 50 ml